Related Experiment Videos
Crystal structures of human factor Xa complexed with potent inhibitors
S Maignan1, J P Guilloteau, S Pouzieux
1Department of Structural Biology, Aventis Pharma, 13, Quai J. Guesde, F-94403 Vitry/Seine, France.
Journal of Medicinal Chemistry
|September 1, 2000
Summary
Researchers crystallized factor Xa (FXa), a key enzyme in blood clotting, enabling new drug design. Structural analysis of FXa inhibitors reveals insights into their specificity for developing potent antithrombotics.
Area of Science:
- Biochemistry
- Structural Biology
- Pharmacology
Background:
- Factor Xa (FXa) is a serine protease crucial for the coagulation cascade.
- FXa is a significant target for developing novel antithrombotic agents.
- Limited structural data exists for ligand/FXa complexes due to crystallization challenges.
Purpose of the Study:
- To establish reproducible crystallization conditions for human des-Gla1-45 coagulation FXa.
- To determine the crystal structures of noncovalent inhibitors complexed with FXa.
- To provide structural insights for the design of potent and bioavailable FXa inhibitors.
Main Methods:
- Developed reproducible crystallization conditions for human des-Gla1-45 coagulation FXa.
- Improved crystal diffraction quality to approximately 2.1 Å.
- Determined crystal structures of three noncovalent FXa inhibitors, including benzamidine derivatives and surrogates.
Main Results:
- Achieved high-quality crystals of FXa, facilitating structure-based drug design.
- Observed canonical binding of benzamidine-containing inhibitors, typical for serine proteases.
- Identified that benzamidine surrogates lack direct hydrogen bonds with Asp189 in the S1 pocket.
Conclusions:
- The structural data elucidates the specificity of FXa inhibitors.
- Provides a foundation for designing more effective and bioavailable FXa inhibitors.
- Advances the development of new antithrombotic therapies targeting FXa.